Skip to main content
Equibles

GNMSF · Genmab A/S

Track GNMSF — free

Use GNMSF with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GNMSF.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$396.97 At close · Oct 5
Rebalance outlook locked
Market Cap
$21.72B
Shares
614.90M
Volume · Oct 5 1656 Avg daily vol (3M) 1680

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$396.97 Open$355.00 Day$351.17–396.97 52W close$232.34–396.97 Avg vol 30d2K Last earningsNov 5, 2026 DataJan 2020–Oct 2026

Up next

Next earnings call
Nov 5, 2026 Scheduled · in 4 wks
Q1 2026 earnings call transcript
call held May 7, 2026

Guidance & track record

Latest guidance · from the Earnings Call filed May 7, 2026
Operating expenses · 2026 $2.7B – $2.9B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $296 › 200d $267 — 50d above 200d
Institutional flow Accumulating
5 of 293 funds reported for Sep 30 · net +450 sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
No short-interest data
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
293 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $232 Now $397 · 100% Range high $397
vs 200-day avg +49% vs 50-day avg +34%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GNMSF
Genmab A/S
this stock
$21.72B +26.4% — — —
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
293
% held
17.4%
Reported
5 of 293
Top holder
Paradigm Biocapital Advis…
Held Float
View
Short & Settlement
Fails to Deliver
FTD shares
5.0K
Value
$166.2K
As of
Sep 9, 2026
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$50.0K–$100.0K
Traded
Jul 10, 2023
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 5, 2026
This year
53
View
Proposed Sales
Value
$67.2K
Shares
1.3K
Filed
Jun 17, 2025
View
Earnings & Events
Webcasts Upcoming
Next webcast
Oct 7, 2026
Last webcast
Sep 22, 2026
View
Investor Relations
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
GNMSF +13.4% +34.6% +28.9% +11.8% +26.4%
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY +12.2% +34.0% +17.3% +10.2% +12.8%
Key facts CIK 1434265 CUSIP 372303206 Visit website Investor relations